Skip to main content

Table 1 Baseline characteristics of HIV-infected participants enrolled in a randomized trial comparing directly administered antiretroviral therapy to self administered therapy in opioid treatment programs, Baltimore, Maryland.

From: Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs

Characteristic

Enrolled in studya(n = 107)

Declined to participatea(n = 12)

Opioid treatment program (enrollment site)

  

   1

39 (36)

2 (17)

   2

35 (33)

1 (8)

   3

8 (8)

0

   4

14 (13)

9 (75)

   5

11 (10)

0

Female

51 (48)

7 (58)

Race

  

   African American

88 (82)

7 (58)

   Caucasian/other

19 (18)

5 (42)

Age, years

47 (41-51)

46 (38-51)

Education

  

   Less than high school graduate

51 (48)

 

   High school graduate or equivalent

36 (34)

 

   Any college, n (%)

20 (19)

 

Marital status

  

   Married or live with partner

17 (16)

 

   Never married

54 (51)

 

   Widowed

9 (8)

 

   Divorced or separated

27 (25)

 

Considers himself/herself to be homeless

32 (30)

 

Housing/living situation

  

   Own a house

3 (3)

 

   Rent an apartment/house

49 (46)

 

   Stay with family or friends

35 (33)

 

   Residential drug treatment

5 (5)

 

   Other residential facility or institution

11 (10)

 

   Live on street or in single room occupancy hotel

4 (4)

 

Employed

16 (15)

 

Duration of methadone or buprenorphine treatment, months

11 (2-49)

 

Receiving methadone

99 (93)

 

   Methadone dose, mg

90 (70-120)

 

Receiving buprenorphine

8 (7)

 

   Buprenorphine dose, mg

19 (14-27)

 

Depression scoreb

11 (5-15)

 

Urine drug test, positive results

  

   Cocaine

42 (40)c

 

   Benzodiazepine

14 (13)c

 

   Opiate (morphine/codeine)

21 (20)c

 

   Oxycodone

1 (1)c

 

Nadir CD4 count, cells/mm3

102 (30-218)

 

Current CD4 count, cells/mm3

182 (69-309)

 

HIV RNA log10 copies/mL

4.7 (4.0-5.1)

 

Hospitalized in prior 3 months

34 (32)

 

Prior AIDS-defining opportunistic condition

66 (62)

 

Hepatitis C antibody positive

87 (81)

 

Antiretroviral naive

21 (20)

 

Category of prescribed antiretroviral regimen

  

   PI + NRTIs

83 (78)

 

   NNRTI + NRTIs

16 (15)

 

   NRTIs only

1 (1)

 

   Other

7 (7)

 

Drug classes included in antiretroviral regimen (not mutually exclusive)

  

   NRTI

97 (91)

 

   Ritonavir-boosted PI

85 (79)

 

   PI (not boosted with ritonavir)

4 (4)

 

   NNRTI

21 (20)

 

   Integrase inhibitor

7 (7)

 

Dosing frequency of prescribed antiretroviral regimen

  

   Once daily

65 (61)

 

   Twice daily

42 (39)

 
  1. PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.
  2. a Values are frequency (%) or median (interquartile range)
  3. b Center for Epidemiologic Studies Depression (CES-D) Scale (7). Higher values indicate more numerous or more severe depressive symptoms (range 0 to 30).
  4. c From 106 subjects.